Detailed Narrative
Robust Profitability and Margin Expansion
Strides Pharma achieved strong profitability in Q3 FY26, with gross margins exceeding 60% and overall gross margins reaching 59.8%. This led to a 12% year-on-year increase in EBITDA, which stood at Rs. 236 crores, marking the highest quarterly EBITDA in the company's history. The EBITDA margin for the quarter was 19.8%, contributing to a 39% YoY growth in operational PAT to Rs. 128 crores and an operational EPS of Rs. 13.9.
Ex-U.S. Markets as a Key Growth Driver
Ex-U.S. markets emerged as a significant growth engine, contributing 47% of the total Q3 FY26 revenues and demonstrating a robust 20% year-on-year growth. Within this segment, Other Regulated Markets (ORM) grew 21% YoY to $48 million, while Growth Markets delivered $16.6 million, up 19% YoY. The company's long-term strategy aims for Ex-U.S. markets to mirror the U.S. markets in terms of revenue contribution within two years.
U.S. Business Performance and Strategic Outlook
The U.S. business experienced a largely flat revenue performance at $70 million compared to the previous year. This was attributed to a muted flu season, increased competition, and slower-than-expected quota allocations for control substances. Despite these challenges, Strides remains committed to its FY28 U.S. revenue aspiration of $400 million, supported by the relaunch of dormant products, normalization of control substances, and ongoing R&D investments.
Strengthening Balance Sheet and Capital Efficiency
The company continued to strengthen its balance sheet, improving the debt/EBITDA ratio to 1.59x and achieving a Return on Capital Employed (ROCE) of 15.8%. Net debt reduced by Rs. 169 crores on a constant currency basis over the nine-month period, despite a negative currency impact of Rs. 83 crores, bringing the total net debt to Rs. 1,436 crores. The cash-to-cash cycle was 124 days, slightly higher due to business mix and holidays, but expected to remain within the 120-125 day range.
Strategic Investments and Future Pipeline
Strides invested Rs. 284 crores in CAPEX during the nine-month period, covering both tangible and intangible assets, including the acquisition of targeted global product rights. The company's maintenance CAPEX for FY26 is projected to be in the range of Rs. 100-125 crores. Strategic investments are also being made in complex areas such as control substances, nasal sprays, and 505(b)(2) programs, with R&D programs expected to start generating revenue within the next 12-18 months.
Management Changes and ESG Focus
The company announced the appointment of Peter Hardwick as CEO of North American Business, bringing 30 years of pharmaceutical experience to drive sustainable growth in the region. Nandini Matiyani also joined as Executive VP of HR to lead global people agenda. Strides improved its ESG score from 75 to 80, reflecting continued focus on responsible growth, compliance, and strong governance practices.